Similar to our results, a retrospective analysis with melanoma patients treated with ipilimumab also showed that increases in absolute lymphocyte counts at 2–8 weeks and circulating CD4+ and CD8+ T cells at 8–14 weeks were associated with positive clinical outcomes (21). Here, CD8A is linked to melanoma.